Is Mounjaro the same as Zepbound?

Same molecule, same manufacturer, same six strengths from 2.5 mg to 15 mg, same four devices and the same escalation rule. Different labels: Mounjaro (NDA215866) is approved for type 2 diabetes and cardiovascular risk reduction in type 2 diabetes, Zepbound (NDA217806) for weight reduction and for obstructive sleep apnoea in adults with obesity. Neither label authorises substituting one for the other, and neither is approved for the other’s indication.

What is the maintenance dose of Mounjaro?

The label does not name one. The word "maintenance" does not appear anywhere in the Mounjaro prescribing information — zero occurrences in the whole document — because the only stated reason to increase the dose is that additional glycaemic control is needed. Any of the six strengths can therefore be a destination. Zepbound is the label that names maintenance dosages: 5 mg, 10 mg or 15 mg for weight reduction, 10 mg or 15 mg for sleep apnoea.

How fast can the dose go up?

No faster than 2.5 mg every four weeks, which puts 15 mg at week 21 at the earliest if every step is taken at the minimum interval. The label’s words are "increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose" — "at least" has no upper bound, so a longer hold is entirely within the label and a patient on 5 mg at month six is not behind schedule.

Can children take Mounjaro?

For type 2 diabetes, patients 10 years of age and older, at up to 10 mg once weekly. The label reports that this was supported by a 30-week randomised, double-blind, placebo-controlled trial with a 22-week open-label extension in 99 paediatric patients, and that safety and effectiveness have not been established below 10 years of age. The KwikPen carries a separate line: it is not recommended for self-administration by paediatric patients.

How long can a Mounjaro pen stay out of the fridge?

It depends which device. A single-dose pen or single-dose vial can be kept unrefrigerated at up to 30 °C for a total of 21 days and is then discarded. An unopened multi-dose vial or KwikPen kept at room temperature is thrown away after 30 days. Once opened, a multi-dose vial or KwikPen is discarded at whichever comes first of 30 days at room temperature, 30 days after first use, or four weekly doses — even if medicine is left in it.

Is Mounjaro approved for weight loss?

No. Its two indications are glycaemic control in type 2 diabetes in adults and patients aged 10 and older, and reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk. Weight reduction is a labelled indication of Zepbound, which is the same molecule under a different brand — and because it is a different application, the same milligram figure carries a different set of instructions with it.

What happens if a weekly Mounjaro dose is missed?

The label states: "If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day." The day of the week can also be changed, provided at least 3 days (72 hours) separate two doses. That 4-day window is narrower than the 5 days the Ozempic label allows, so a rule learned on one GLP-1 does not carry over.

Brand — one of two labels for one molecule

Mounjaro

Same molecule as Zepbound, same six strengths, same devices, same escalation rule — and a label that never once uses the word "maintenance", carries a paediatric ceiling Zepbound has no version of, and is not approved for weight loss.

Molecule: tirzepatide
Manufacturer: Eli Lilly and Company
Products under this name: 1
Last reviewed: September 2026

Why a Mounjaro dose and a Zepbound dose are not the same instruction

Tirzepatide is sold in the United States as two brands from one manufacturer. MOUNJARO (NDA215866) is approved for glycaemic control in type 2 diabetes and for cardiovascular risk reduction in type 2 diabetes at high risk. ZEPBOUND (NDA217806) is approved for weight reduction and long-term maintenance and for moderate to severe obstructive sleep apnoea in adults with obesity. Neither is approved for the other’s indications, and there is no labelled switch between them in either direction.

The confusing part is that everything physical about them matches. Both ship as a single-dose pen, a single-dose vial, a four-dose multi-dose vial and a four-dose KwikPen, in the same six strengths from 2.5 mg to 15 mg. Both start at 2.5 mg once weekly and rise in 2.5 mg increments after at least four weeks. Both are stored the same way, discarded on the same schedule and carry the same boxed warning. Someone holding two cartons would find the numbers on them identical.

What differs is the meaning the label attaches to each rung. The word "maintenance" does not appear anywhere in the Mounjaro prescribing information — not once in the whole document — while it appears twenty-one times in Zepbound’s, which names 5 mg, 10 mg and 15 mg as maintenance dosages and states that 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage". On Mounjaro every rung is a place you can stay, because the only reason to climb is that additional glycaemic control is needed. On Zepbound the bottom rung is explicitly not a destination. A dose chart is portable between the two brands; the instruction attached to it is not.

What is true of Mounjaro and not of tirzepatide

Each row is something a reader would reasonably assume belongs to the molecule, and does not. These are the facts that change when the brand name on the carton changes, while the drug inside it does not.

Attribute	Mounjaro	Elsewhere, same molecule
What it is approved to treatWeight loss is not a labelled indication of Mounjaro and diabetes is not a labelled indication of Zepbound. Prescribing either for the other’s purpose is off-label use of that brand, even though the molecule inside the pen is identical and the pen itself is identical.	Glycaemic control in type 2 diabetes, in adults and in patients 10 years of age and older; and reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them.	Zepbound, the same molecule from the same manufacturer, is approved for weight reduction and long-term weight maintenance, and for moderate to severe obstructive sleep apnoea in adults with obesity.
Whether the label names a maintenance doseThe same 2.5 mg pen is a legitimate long-term dose under one brand and explicitly not a maintenance dose under the other. Anyone told "2.5 mg is just the starter dose" has been given Zepbound’s rule, and it is not in this label.	It does not. The word "maintenance" does not occur anywhere in the Mounjaro prescribing information. Every rung from 2.5 mg to 15 mg is a place a patient may remain, because the only stated reason to climb is that additional glycaemic control is needed.	The Zepbound label uses the word twenty-one times, names 5 mg, 10 mg and 15 mg as recommended maintenance dosages, and states that 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage".
How many maximum doses the label statesA 12.5 mg or 15 mg Mounjaro pen is above the labelled ceiling for a patient under 18, while the same pen is within the ceiling for his father. The maximum is a property of the patient and the brand together, never of the molecule.	Two: 15 mg once weekly in adults and 10 mg once weekly in paediatric patients, printed as a two-line list under one heading.	Zepbound states one: "The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly", with no paediatric figure because it has no paediatric use.
Whether children may take itOne molecule, one age group, two opposite labelled positions decided entirely by which carton it came in — and the KwikPen carries an additional line saying it is not recommended for self-administration by paediatric patients even where the drug is.	Established in patients 10 years of age and older with type 2 diabetes, supported by a 30-week randomised placebo-controlled trial with a 22-week open-label extension in 99 paediatric patients. Not established below 10 years of age.	Zepbound states without qualification that its safety and effectiveness have not been established in pediatric patients, for either of its indications.
What makes the dose go upEvery week number on a Mounjaro ladder is the earliest a step may begin, never a date a patient is behind on. A titration planner built from the Zepbound wording will show a patient as overdue for an increase that his own label never asked for.	A clinical condition: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." Nothing on this label escalates on the calendar.	Zepbound names the first step as an event rather than a decision — "After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly" — before handing the rest to response and tolerability.
Whether the dose depends on the indicationOn Zepbound, 5 mg is a maintenance dose for one indication and below the maintenance range for the other. Carrying that idea across to Mounjaro invents a rule its label does not contain.	It does not. One ladder serves both indications; the label gives no separate dosage for cardiovascular risk reduction and no indication-specific target within the 2.5 mg to 15 mg range.	Zepbound’s maintenance dosage changes with the indication: 5 mg, 10 mg, 15 mg for weight reduction, but only 10 mg or 15 mg for obstructive sleep apnoea.

Boxed warning — risk of thyroid C-cell tumors

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Quoted from the boxed warning on the approved product label. See the full prescribing information for the complete warning.

Mounjaro injection

Dosage form: Injection, solution
Route: Subcutaneous, in the abdomen, thigh or back of the upper arm
Marketing category: NDA — NDA215866
Label read: SPL version 40, effective August 27, 2026

What this product is approved to treat

—as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
—to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

The labelled ladder

When	Dose	What the label attaches to this step
Weeks 1–4	2.5 mg once weekly	The label's starting dosage: "The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly." Unlike ZEPBOUND, this label does not call it an initiation-only dose, and does not exclude it as a destination.
Weeks 5–8	5 mg once weekly	Conditional, not scheduled: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." The week shown is the earliest this step may begin if every prior step is held for the minimum; the label sets no upper limit on how long a dose may be held.
Weeks 9–12	7.5 mg once weekly	Conditional, not scheduled: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." The week shown is the earliest this step may begin if every prior step is held for the minimum; the label sets no upper limit on how long a dose may be held.
Weeks 13–16	10 mg once weekly	Conditional, not scheduled: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." The week shown is the earliest this step may begin if every prior step is held for the minimum; the label sets no upper limit on how long a dose may be held.
Weeks 17–20	12.5 mg once weekly	Conditional, not scheduled: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." The week shown is the earliest this step may begin if every prior step is held for the minimum; the label sets no upper limit on how long a dose may be held.
Week 21 onward	15 mg once weekly	Conditional, not scheduled: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." The week shown is the earliest this step may begin if every prior step is held for the minimum; the label sets no upper limit on how long a dose may be held. The adult ceiling. The label's paediatric ceiling is lower — 10 mg once weekly in patients 10 years of age and older.

Ceiling. Two ceilings, not one. The label states: "The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients." Zepbound, the other tirzepatide brand, names one maximum — 15 mg for all indications — and has no paediatric dosage at all.

How it is supplied

Presentation	Total strength	Concentration	Delivers
Mounjaro single-dose pen or single-dose vial	2.5 mg/0.5 mL	5 mg/mL — computed from the fill volume; section 3 prints no mg/mL for the single-dose presentations	One dose of 2.5 mg
Mounjaro single-dose pen or single-dose vial	5 mg/0.5 mL	10 mg/mL — computed from the fill volume; section 3 prints no mg/mL for the single-dose presentations	One dose of 5 mg
Mounjaro single-dose pen or single-dose vial	7.5 mg/0.5 mL	15 mg/mL — computed from the fill volume; section 3 prints no mg/mL for the single-dose presentations	One dose of 7.5 mg
Mounjaro single-dose pen or single-dose vial	10 mg/0.5 mL	20 mg/mL — computed from the fill volume; section 3 prints no mg/mL for the single-dose presentations	One dose of 10 mg
Mounjaro single-dose pen or single-dose vial	12.5 mg/0.5 mL	25 mg/mL — computed from the fill volume; section 3 prints no mg/mL for the single-dose presentations	One dose of 12.5 mg
Mounjaro single-dose pen or single-dose vial	15 mg/0.5 mL	30 mg/mL — computed from the fill volume; section 3 prints no mg/mL for the single-dose presentations	One dose of 15 mg
Mounjaro multi-dose vial or single-patient-use KwikPen (4 doses)	10 mg/2.4 mL	4.17 mg/mL	4 doses of 2.5 mg/0.6 mL
Mounjaro multi-dose vial or single-patient-use KwikPen (4 doses)	20 mg/2.4 mL	8.33 mg/mL	4 doses of 5 mg/0.6 mL
Mounjaro multi-dose vial or single-patient-use KwikPen (4 doses)	30 mg/2.4 mL	12.5 mg/mL	4 doses of 7.5 mg/0.6 mL
Mounjaro multi-dose vial or single-patient-use KwikPen (4 doses)	40 mg/2.4 mL	16.7 mg/mL	4 doses of 10 mg/0.6 mL
Mounjaro multi-dose vial or single-patient-use KwikPen (4 doses)	50 mg/2.4 mL	20.8 mg/mL	4 doses of 12.5 mg/0.6 mL
Mounjaro multi-dose vial or single-patient-use KwikPen (4 doses)	60 mg/2.4 mL	25 mg/mL	4 doses of 15 mg/0.6 mL

Administration, as the label words it

—Administer MOUNJARO once weekly, any time of day, with or without meals.
—Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose.
—If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.
—The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
—Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.
—MOUNJARO KwikPen is not recommended for self-administration by pediatric patients. MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired.
—When using MOUNJARO with insulin, administer as separate injections and never mix.

Storage

Single-dose pen or single-dose vial: Refrigerated, 2 °C to 8 °C (36 °F to 46 °F), in the original carton to protect from light; Until expiration date
Single-dose pen or single-dose vial, if needed: Unrefrigerated, not to exceed 30 °C (86 °F); 21 days total, then discard
Multi-dose vial or KwikPen, unopened: Refrigerated 2 °C to 8 °C, or at room temperature up to 30 °C; Expiration date if refrigerated; 30 days if at room temperature
Multi-dose vial or KwikPen, after first use: Refrigerated 2 °C to 8 °C or at room temperature up to 30 °C, in the original carton; Whichever comes first: 30 days at room temperature, 30 days after first use, or 4 weekly doses

Children and adolescents

The safety and effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established. The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.

This statement belongs to Mounjaro injection. It is not a statement about tirzepatide, and another brand of the same molecule may say the opposite.

The same molecule under other brand names

Everything below is tirzepatide. None of it is Mounjaro, and a dose from one column carried into another is not a smaller or larger version of the same instruction — it is a different product’s schedule.

Brand	Form	Approved for	Ladder	Maximum
Zepbound	Subcutaneous, once weekly — the same four devices in the same six strengths	Weight reduction and long-term weight maintenance in adults with obesity or overweight with a comorbidity; moderate to severe obstructive sleep apnoea in adults with obesity	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg	15 mg once weekly for all indications, adults only

Switching between products

No switch between the two brands is authorised, and taking both is not recommended

MOUNJARO contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

Mounjaro and Zepbound

What this page does not tell you

Price — list, cash or copay: No price appears anywhere on this page, and no price is emitted in its structured data. Mounjaro pricing varies by presentation, pharmacy, insurance design and manufacturer programme, and we could not find a source for a current US figure that we could cite and re-verify the way every other number here is cited. A stale or wrong price is the most consequential thing a page like this could print, so the field is absent rather than estimated.
A Mounjaro-to-Zepbound dose conversion: There is nothing to convert and nothing to state. The two brands are the same molecule at the same six strengths, so a milligram is a milligram — but neither label authorises moving a patient from one to the other, neither describes what happens when you do, and the Limitations of Use section of each says coadministration with another tirzepatide-containing product is not recommended. Whether a switch is appropriate, and at what dose, is a prescriber’s decision that no label on file supports.
How much weight Mounjaro causes: Mounjaro is not indicated for weight reduction, so its label reports no weight-loss endpoint as an efficacy result to quote. Figures circulating for "tirzepatide weight loss" come from the Zepbound programme, in populations enrolled for obesity rather than for diabetes, and reproducing them on this page would attach a Zepbound result to a Mounjaro prescription.
How many syringe units a dose equals: Every Mounjaro presentation is fixed-dose: the single-dose pen and single-dose vial hold one injection, and the multi-dose vial and KwikPen deliver four 0.6 mL doses that are set by the device, not measured by the patient. The label’s only instruction about a syringe is to use one capable of measuring a 0.5 mL or 0.6 mL dose from a vial. Any "tirzepatide units chart" is describing a compounded powder reconstituted at a concentration the compounder chose, which is a different product with no approved labelling.

Frequently asked questions

Is Mounjaro the same as Zepbound?: Same molecule, same manufacturer, same six strengths from 2.5 mg to 15 mg, same four devices and the same escalation rule. Different labels: Mounjaro (NDA215866) is approved for type 2 diabetes and cardiovascular risk reduction in type 2 diabetes, Zepbound (NDA217806) for weight reduction and for obstructive sleep apnoea in adults with obesity. Neither label authorises substituting one for the other, and neither is approved for the other’s indication.
What is the maintenance dose of Mounjaro?: The label does not name one. The word "maintenance" does not appear anywhere in the Mounjaro prescribing information — zero occurrences in the whole document — because the only stated reason to increase the dose is that additional glycaemic control is needed. Any of the six strengths can therefore be a destination. Zepbound is the label that names maintenance dosages: 5 mg, 10 mg or 15 mg for weight reduction, 10 mg or 15 mg for sleep apnoea.
What is the maximum dose of Mounjaro?: Two figures, depending on the patient. The label states: "The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients." Zepbound names a single maximum of 15 mg for all indications and carries no paediatric dosage at all, so the 10 mg ceiling is a Mounjaro fact rather than a tirzepatide fact.
How fast can the dose go up?: No faster than 2.5 mg every four weeks, which puts 15 mg at week 21 at the earliest if every step is taken at the minimum interval. The label’s words are "increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose" — "at least" has no upper bound, so a longer hold is entirely within the label and a patient on 5 mg at month six is not behind schedule.
Can children take Mounjaro?: For type 2 diabetes, patients 10 years of age and older, at up to 10 mg once weekly. The label reports that this was supported by a 30-week randomised, double-blind, placebo-controlled trial with a 22-week open-label extension in 99 paediatric patients, and that safety and effectiveness have not been established below 10 years of age. The KwikPen carries a separate line: it is not recommended for self-administration by paediatric patients.
How long can a Mounjaro pen stay out of the fridge?: It depends which device. A single-dose pen or single-dose vial can be kept unrefrigerated at up to 30 °C for a total of 21 days and is then discarded. An unopened multi-dose vial or KwikPen kept at room temperature is thrown away after 30 days. Once opened, a multi-dose vial or KwikPen is discarded at whichever comes first of 30 days at room temperature, 30 days after first use, or four weekly doses — even if medicine is left in it.
Is Mounjaro approved for weight loss?: No. Its two indications are glycaemic control in type 2 diabetes in adults and patients aged 10 and older, and reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk. Weight reduction is a labelled indication of Zepbound, which is the same molecule under a different brand — and because it is a different application, the same milligram figure carries a different set of instructions with it.
What happens if a weekly Mounjaro dose is missed?: The label states: "If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day." The day of the week can also be changed, provided at least 3 days (72 hours) separate two doses. That 4-day window is narrower than the 5 days the Ozempic label allows, so a rule learned on one GLP-1 does not carry over.

Sources

Next steps

Compare online GLP-1 providersWho prescribes branded tirzepatide, who prescribes compounded, and what each one requires before they will.Plan a titration against the labelEnter a start date and see the earliest week each step may begin under the 2.5 mg increments after at least 4 weeks on the current dose rule.

Other brands

Educational reference, not medical advice. Dose, product and whether a GLP-1 is appropriate at all are decisions for your prescriber. This page reports what two FDA labels state; it does not recommend a dose.